India's Aurobindo Pharma dermatitis drug could become $300 million brand, says HSBC

Aurobindo Pharma

18/02/2026 07:24

** HSBC raises Aurobindo Pharma ARBN.NS PT from 1,380 rupees to 1,415 rupees, maintains "buy"

** Hike comes after US FDA approves Adquey, a non-steroid topical treatment for dermatitis

** Says Adquey has potential to become a $250-300 million brand and that ARBN needs to hire specialist salespeople

** Entry in next 6-7 months could help it capture share in a supply‑constrained category with strong prescription demand - HSBC

** ARBN up 1% at 1,157 rupees since Friday, when FDA approval was received

** 26 analysts covering ARBN have "buy" rating on avg; median PT is 1,380 rupees - data compiled by LSEG

** YTD, stock down 2.5%

(Reporting by Urvi Dugar in Bengaluru)

((UrviManoj.Dugar@thomsonreuters.com; +91 9558725583;))